ClinicalTrials.gg
CompletedNCT00141960Updated Nov 21, 2011

Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease

A Phase 2/3 interventional study of Famotidine in Gastroesophageal Reflux, sponsored by Astellas Pharma Inc. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-11-21.

Sponsored by Astellas Pharma Inc · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Gastroesophageal Reflux with a site in Japan — none open to participants now, none under way, none of them phase 3. Gastroesophageal Reflux · Japan.

Enrollment
4th of 13
480 · median 300
Started
2005
with 2 others
Phase 2/3
2 of 15
none open now
Registered
1st of 15
by date
Lead sponsor
1 of 15
Astellas Pharma Inc

Among the 15 studies in Gastroesophageal Reflux with a site in Japan, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2005, is one of 2 in phase 2/3, and was the 1st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 15 studies in Gastroesophageal Reflux with a site in Japan is open now. The open studies under Gastroesophageal Reflux, anywhere →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Gastroesophageal Reflux with a site in Japan as a file.
02

Study summary

Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents. While most of the patients given the diagnosis of GERD do not exhibit endoscopically obvious impairment in esophageal mucous membrane, they have subjective symptoms of non-erosive GERD including heartburn. But no drug has been launched in Japan, which targets non-erosive GERD. This study will examine the efficacy and safety of famotidine in subjects with non-erosive GERD.

03

Conditions studied

  • Gastroesophageal Reflux

Keywords

  • Treatment efficacy
  • Treatment effectiveness
  • Gastrointestinal Diseases
  • Reflux, Gastroesophageal
  • GERD
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have heartburn with non-erosive gastroesophageal reflux disease.

Exclusion criteria

Exclusion Criteria:

  • Patients have diseases which interfere with evaluation of the efficacy and safety in this study.
  • Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.
  • Patients have severe cardiovascular, hepatic, renal and hematological disorders.
  • Patients are allergic to or have a history of drug allergy to H2RA.
  • Patients have or have a history of malignant tumors.
  • Patients are pregnant or a lactating mother.
  • Patients have participated in other clinical studies less than 12 weeks prior to submitting the .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
480 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of days with no heart burn in the treatment period

Secondary outcomes

  1. Disappearance of heart burn

  2. Severity of heart burn

  3. Frequency of heart burn

  4. Patient's final global improvement rating

  5. Other symptoms (e.g.,reflux sensation of gastric fluid, discomfort of pharynges)

07

Study locations

7 sites
  • Hokkaido region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Kyushu region, Japan
  • Shikoku region, Japan
  • Tohoku region, Japan
  • Tokai region, Japan
08

References and documents

Publications

  • Hongo M, Kinoshita Y, Haruma K. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. J Gastroenterol. 2008;43(6):448-56. doi: 10.1007/s00535-008-2186-5. Epub 2008 Jul 4. PubMed 18600389 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141960
First posted
Sep 2, 2005
Start date
Sep 2005
Last update
Nov 21, 2011

Study contacts

Study Director
study chair · Clinical Development III, Astellas Pharm. Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Famotidine

Start the discussion